Oral palonosetron noninferior to IV formulation for CINV prevention
the ONA take:
Oral palonosetron is non-inferior to intravenous palonosetron for the prevention of cisplatin-related chemotherapy-induced nausea and vomiting (CINV), according to a study published in the October 2015 issue of the journal Supportive Care in Cancer.
For the study, a team of researchers led by Prof. Dr. med. Meinolf Karthaus of the Department of Hematology and Oncology at Klinikum Neuperlach in Munich, Germany, sought to compare the efficacy and safety of oral palonosetron with intravenous palonosetron for the prevention cisplatin-based highly emetogenic chemotherapy.
Researchers enrolled 743 chemotherapy-naive adults with malignant solid tumors initiating cisplatin-based chemotherapy. Patients were randomly assigned to receive palonosetron 0.50mg orally or 0.25mg intravenously plus oral dexamethasone.
Results showed that the complete response rate in the acute phase was higher than 86% in both treatment arms and the safety profiles were comparable.
Treatment-emergent adverse events related to palonosetron occurred in 3.2% of patients in the oral palonosetron group and 6.5% in the intravenous group.
Oral palonosetron is non-inferior to intravenous palonosetron for the prevention of cisplatin-related chemotherapy-induced nausea and vomiting.
- Acupuncture Improves Postoperative Symptoms in Women Undergoing Surgery for Breast Cancer
- Prehabilitation Program Improves Preoperative Fitness in Patients With Colorectal Cancer
- Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma
- Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
- Omitting RT in Certain Older Women With Early Breast Cancer is Safe
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Community Breast Navigation Program Improved Breast Screening Rates in Underserved African American and Latino Women
- Live-streamed Videos Address End-of-Life Planning, Decision-making
- Metastatic Disease Linked to Patients Reporting Diminished QoL
- History of Bilateral Salpingo-oophorectomy, Hormone Replacement Therapy Are Predictive of Breast Density at Cancer Diagnosis
- Mammographically Occult Contralateral Breast Cancer Detection is Effective With Preoperative MRI
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|